Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Ensysce Biosciences, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +6 vs. Q2 2025
- Shares held
- 351.7K
- +172.5K (+96.3%) vs. Q2 2025
- Total value
- $833.7K
- +$434.9K (+109.0%) vs. Q2 2025
- New holders
- 8
- 3 more added
- Sold out
- 2
- 2 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Assetmark, Inc | 13 | $31 | 0.00% | +13 | New |
| Bank of America Corp | 24 | $57 | 0.00% | +5+26.3% | Added |
| BlackRock, Inc. | 65 | $154 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 418 | $991 | 0.00% | −1,918−82.1% | Reduced |
| UBS Group AG | 800 | $1.90K | 0.00% | +446+126.0% | Added |
| Tower Research Capital LLC (TRC) | 1,348 | $3.19K | 0.00% | −21−1.5% | Reduced |
| FNY Investment Advisers, LLC | 3,000 | $7.00K | 0.00% | 00.0% | Unchanged |
| Tru Independence Asset Management 2, LLC | 10,500 | $24.9K | 0.02% | +10,500 | New |
| XTX Topco Ltd | 10,957 | $26.0K | 0.00% | +10,957 | New |
| Geode Capital Management, LLC | 13,030 | $30.9K | 0.00% | +2,869+28.2% | Added |
| Virtu Financial LLC | 14,222 | $34.0K | 0.00% | +14,222 | New |
| Citadel Advisors LLC | 14,518 | $34.4K | 0.00% | +14,518 | New |
| Renaissance Technologies LLC | 15,574 | $36.9K | 0.00% | +15,574 | New |
| Vanguard Group Inc | 36,708 | $87.0K | 0.00% | +36,708 | New |
| DRW Securities, LLC | 69,145 | $163.9K | 0.01% | +69,145 | New |
| Adage Capital Partners GP, L.L.C. | 74,711 | $177.1K | 0.00% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 86,666 | $205.4K | 0.01% | 00.0% | Unchanged |
| Morgan Stanley | 0 | $0 | 0.00% | −378−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −94−100.0% | Sold out |